Return on Tangible Equity: The amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity. Calculated as: Income from Continuing Operations / Tangible Shareholders Equity
Cadrenal Therapeutics, Inc. (CVKD) had Return on Tangible Equity of -483.34% for the most recently reported fiscal year, ending 2025-12-31.
| Income Statement Financials | |
-- |
|
$-13.24M |
|
-- |
|
-- |
|
$13.46M |
|
$-13.46M |
|
$0.22M |
|
$-13.24M |
|
$-13.24M |
|
$-13.24M |
|
$-13.24M |
|
$-13.24M |
|
$-13.24M |
|
$-13.46M |
|
$-13.45M |
|
1.99M |
|
1.99M |
|
$-6.64 |
|
$-6.64 |
|
| Balance Sheet Financials | |
$4.32M |
|
$0.01M |
|
$0.01M |
|
$4.33M |
|
$1.59M |
|
-- |
|
-- |
|
$1.59M |
|
$2.74M |
|
$2.74M |
|
$2.74M |
|
2.34M |
|
| Cash Flow Statement Financials | |
$-12.60M |
|
$-0.01M |
|
$6.60M |
|
$10.02M |
|
$4.01M |
|
$-6.01M |
|
$1.94M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
2.72 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-12.61M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-483.34% |
|
|
Return on Tangible Equity |
-483.34% |
-305.95% |
|
-483.34% |
|
$1.17 |
|
$-6.32 |
|
$-6.32 |
|